Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer

Cancer Research

Volumn 71, Issue 24, 2011, Pages 7597-7607

  Hou, Xiaonan ^a   Huang, Fei ^b   Macedo, Luciana F ^c   Harrington, Sean C ^a   Reeves, Karen A ^b   Greer, Ann ^b   Finckenstein, Friedrich Graf ^b   Brodie, Angela ^c   Gottardis, Marco M ^b   Carboni, Joan M ^b   Haluska, Paul ^a  

^a MAYO CLINIC   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; ANTINEOPLASTIC AGENT; BMS 754807; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; FULVESTRANT; LETROZOLE; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CELL CYCLE REGULATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; TREATMENT RESPONSE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; ESTRADIOL; ESTROGENS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NITRILES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PYRAZOLES; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; TAMOXIFEN; TRIAZINES; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84255192030     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1080     Document Type: Article

References (47)

1. Baum M, Brinkley DM, Dossett JA, McPherson K, Patterson JS, Rubens RD, et al. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 1983;2:450. (Pubitemid 13043465)
2. Gee JM, Howell A, Gullick WJ, Benz CC, Sutherland RL, Santen RJ, et al. Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. Endocr Relat Cancer 2005;12 Suppl 1:S1-7.
3. Casa AJ, Dearth RK, Litzenburger BC, Lee AV, Cui X. The type I insulinlike growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci 2008;13:3273-87. (Pubitemid 351594682)
4. Maor S, Mayer D, Yarden RI, Lee AV, Sarfstein R, Werner H, et al. Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1. J Endocrinol 2006;191:605-12. (Pubitemid 46210286)
5. Cascio S, Bartella V, Garofalo C, Russo A, Giordano A, Surmacz E. Insulin-like growth factor 1 differentially regulates estrogen receptor-dependent transcription at estrogen response element and AP-1 sites in breast cancer cells. J Biol Chem 2007;282:3498-506. (Pubitemid 47084426)
6. Hamelers IH, van Schaik RF, van Teeffelen HA, Sussenbach JS, Steenbergh PH. Synergistic proliferative action of insulin-like growth factor I and 17 beta-estradiol in MCF-7S breast tumor cells. Exp Cell Res 2002;273:107-17.
7. Lee AV, Weng CN, Jackson JG, Yee D. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 1997;152:39-47. (Pubitemid 27026386)
8. Milano A, Dal Lago L, Sotiriou C, Piccart M, Cardoso F. What clinicians need to know about antioestrogen resistance in breast cancer therapy. Eur J Cancer 2006;42:2692-705. (Pubitemid 44584668)
9. Zhang S, Li X, Burghardt R, Smith R 3rd, Safe SH. Role of estrogen receptor (ER) alpha in insulin-like growth factor (IGF)-I-induced responses in MCF-7 breast cancer cells. J Mol Endocrinol 2005;35:433-47. (Pubitemid 43025570)
10. Santen RJ, Song RX, Masamura S, Yue W, Fan P, Sogon T, et al. Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. Adv Exp Med Biol 2008;630:19-34.
11. Song RX, Zhang Z, Chen Y, Bao Y, Santen RJ. Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology 2007;148:4091-101. (Pubitemid 47105855)
12. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005;11:2063-73. (Pubitemid 40471873)
13. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, von Euler M, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247-58.
14. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-606. (Pubitemid 32451796)
15. Sepp-Lorenzino L. Structure and function of the insulin-like growth factor I receptor. Breast Cancer Res Treat 1998;47:235-53. (Pubitemid 28059820)
16. Dupont J, LeRoith D. Insulin and insulin-like growth factor I receptors: similarities and differences in signal transduction. Horm Res 2001;55 Suppl 2:22-6.
17. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002;277:39684-95. (Pubitemid 35190951)
18. Sciacca L, Costantino A, Pandini G, Mineo R, Frasca F, Scalia P, et al. Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 1999;18:2471-9. (Pubitemid 29206160)
19. Mathieu MC, Clark GM, Allred DC, Goldfine ID, Vigneri R. Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians 1997;109:565-71. (Pubitemid 27495695)
20. Papa V, Pezzino V, Costantino A, Belfiore A,Giuffrida D, Frittitta L, et al. Elevated insulin receptor content in human breast cancer. J Clin Invest 1990;86:1503-10. (Pubitemid 20372597)
21. Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, Longhi A, et al. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res 2009;69:2443-52.
22. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007;13:5834-40. (Pubitemid 47583908)
23. Haluska P, Shaw H, Batzel GN, Molife LR, Adjei AA, Yap TA, et al. Phase I dose escalation study of the anti-IGF-1R monoclonal antibody CP-751,871 in patients with refractory solid tumors. ASCO Meeting Abstracts 2007;25:3586.
24. Jelovac D, Macedo L, Handratta V, Long BJ, Goloubeva OG, Ingle JN, et al. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. Clin Cancer Res 2004;10:7375-81. (Pubitemid 39487727)
25. Macedo LF, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y, Brodie A. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res 2006;66:7775-82. (Pubitemid 44289238)
26. Zhou DJ, Pompon D, Chen SA. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res 1990;50:6949-54. (Pubitemid 20361096)
27. Haluska P, Carboni JM, TenEyck C, Attar RM, Hou X, Yu C, et al. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 2008;7:2589-98.
28. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
29. Haluska P, Hou X, Huang F, Harrington SC, Greer A, Macedo L, et al. Complete IGF signaling blockade by the dual-kinase inhibitor, BMS-754807, is sufficient to overcome tamoxifen and letrozole resistance in vitro and in vivo. Cancer Res 2009;69:402.
30. Hou X, Harrington SC, Macedo LF, Weroha SJ, Brodie A, Haluska P. Hormonal therapies differentially enhance insulin receptor isoform A and erbB receptor up-regulation in response to IGF-1R inhibitor MK-0646 in vivo. Proc Amer Assoc Cancer Res 2009 Apr 18-22. Denver, CO; 2009. p. 2812.
31. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999;19:3278-88. (Pubitemid 29193789)
32. Kaufman PA, Ferrero JM, Bourgeois H, Kennecke H, De Boer R, Jacot W, et al. A randomized, double-blind, placebo-controlled, phase 2 study of AMG 479 with exemestane (E) or fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) metastatic (M) or locally advanced (LA) breast cancer (BC). Cancer Res 2010;70:S1-4.
33. Zhang H, Yee D. The therapeutic potential of agents targeting the type I insulin-like growth factor receptor. Expert Opin Investig Drugs 2004;13:1569-77. (Pubitemid 39625142)
34. Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials-early lessons. J Mammary Gland Biol Neoplasia 2008;13:471-83.
35. Carden CP, Kim ES, Jones RL, Alam SM, Johnson FM, Stephens AW, et al. Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors. J Clin Oncol 2010;28:abstract no. 2530.
36. Desai J, Solomon BJ, Davis ID, Lipton LR, Hicks R, Scott AM, et al. Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors. J Clin Oncol 2010;28:abstract no. 3104.
37. Evans T, Lindsay CR, Chan E, Tait B, Michael SA, Day S, et al. Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors. J Clin Oncol 2010;28:abstract no. 2531.
38. Legault-Poisson S, Jolivet J, Poisson R, Beretta-Piccoli M, Band PR. Tamoxifen-induced tumor stimulation and withdrawal response. Cancer Treat Rep 1979;63:1839-41. (Pubitemid 10138940)
39. Belani CP, Pearl P, Whitley NO, Aisner J. Tamoxifen withdrawal response. Report of a case. Arch Intern Med 1989;149:449-50. (Pubitemid 19058534)
40. Stein W 3rd, Hortobagyi GN, Blumenschein GR. Response of metastatic breast cancer to tamoxifen withdrawal: report of a case. J Surg Oncol 1983;22:45-6. (Pubitemid 13179723)
41. Kristensen CA, Kristjansen PE, Brunner N, Quistorff B, Spang-Thomsen M. Growth inhibition in response to estrogen withdrawal and tamoxifen therapy of human breast cancer xenografts evaluated by in vivo 31P magnetic resonance spectroscopy, creatine kinase activity, and apoptotic index. Cancer Res 1995;55:4146-50.
42. Howell A, Dodwell DJ, Anderson H, Redford J. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 1992;3:611-7.
43. Canney PA, Griffiths T, Latief TN, Priestman TJ. Clinical significance of tamoxifen withdrawal response. Lancet 1987;1:36.
44. Taylor SGt, Gelman RS, Falkson G, Cummings FJ. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med 1986;104:455-61.
45. Bhide SA, Rea DW. Metastatic breast cancer response after Exemestane withdrawal: a case report. Breast 2004;13:66-8. (Pubitemid 38228591)
46. Cigler T, Goss PE. Aromatase inhibitor withdrawal response in metastatic breast cancer. J Clin Oncol 2006;24:1955-6. (Pubitemid 46638998)
47. Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 2009;69:161-70.